OLYMPUS
7.12.2021 07:02:05 CET | Business Wire | Press release
Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states. The medtech leader’s approach involves greater focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases that will increasingly impact the global population, as well as more focused investment in next-generation technologies that will enhance patient care pathways.
Three major principles guide the company’s approach:
-
Focus the portfolio on disease states where Olympus can maximize impact
Olympus will focus on the disease states where it can maximize its positive impact, including those targeted by its Gastrointestinal, Urology, and Respiratory business areas. Aging populations worldwide face increasing levels of chronic disease that present unmet needs matching Olympus’ competitive strengths, as well as opportunities to continue providing solutions for colorectal cancer, benign prostatic hyperplasia, urological stone disease, urinary disease, and lung cancer. Other medical areas will remain important business components and support Olympus’ goal of striving for greater profitability, contributing to the company-wide goal of at least 5-6% annual growth and an operating profit margin of 20% or higher. -
Shape the future by investing in new ways to enhance the standard of care
Olympus will concentrate on a care pathway oriented approach, procedural optimization, and next-generation solutions development. The company’s innovation pipeline includes plans to optimize its endoscope line through complementary single-use scopes; integrate computer-assisted diagnosis, cloud, and endoscopy workflow management technologies; and explore endoluminal therapy breakthroughs. -
Enable Olympus to compete even more effectively on a global scale
The company’s approach includes enabling factors, such as an expanded global R&D network, stronger Medical and Scientific Affairs, and a more centralized Quality Assurance and Regulatory Affairs function. Merger and acquisition momentum is expected to stay strong via the Olympus business development function, which drove significant acquisitions over the past 2 years. Additionally, the new Olympus wholly owned corporate venture capital fund will prioritize early-stage investments and aim to stimulate next-generation innovations.
Olympus’ new direction comes on the back of strong half-year figures, including a record operating profit margin of 18.5% and strong year-on-year growth of 31%, as announced on November 5. Medical business revenue is expected to reach a record high for fiscal year 2022. Olympus also reiterated its goal of operating with a 20%-plus profit margin and a midterm annual growth rate of 5-6% in fiscal year 2023.
Since 2019, Olympus has completed the sale of its Imaging business and announced the impending transition of its Scientific Solutions business into a newly established, wholly owned subsidiary. A package of operational changes brought about enhancements in efficiency, profitability, R&D processes, and customer care.
“We are witnessing stunning changes to the global healthcare industry due to the aging of populations, the rise of chronic diseases, integration of digital technologies, health and biotech advancements and a growing emphasis on less-invasive treatments,” said Yasuo Takeuchi, President and CEO of Olympus. “With the successful transformation of Olympus since 2019, we have become a global medtech leader. Today we have unveiled a unifying value creation direction that is designed to elevate the standard of care, optimize the treatment journey for patients and healthcare professionals, and benefit all stakeholders, while accelerating our ability to deliver on the profitability and growth targets we have set.”
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005877/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 18:00:00 CET | Press release
Four-year global partnership makes WHOOP an Official Partner of Formula 1 bringing physiological insights into the broadcast beginning in 2027 WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physi
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 15:37:00 CET | Press release
Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. The Academy will support two-way knowledge exchange, bringing global expertise to Abu Dhabi while creating opportunities to share Abu Dhabi’s knowledge, expertise and innovation with the world. Inaugural course brought together senior leaders from government, healthcare, research, and industry with local and international scientific experts. Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life s
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 15:30:00 CET | Press release
Soracom suite combines existing platform services for physical AI, available worldwide Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, l
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 15:23:00 CET | Press release
The raise follows the rapid growth of swaps, Variational’s new instrument bringing liquidity from traditional finance on-chain. Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in Se
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 15:00:00 CET | Press release
Players Can Choose Their Quests, Developers Get Measurable Results From Their Games, and Advertisers Get Verified Insight From Players Who Choose to Share Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
